Table 1.
Characteristics of Treated vs Observed Patients With HHV-6B Reactivation
| Baseline Characteristics | Observed (n = 37) | Treated (n = 21) | P Value |
|---|---|---|---|
| Median age (IQR), y | 58 (46.0–66.5) | 63 (26.0–66.5) | .948 |
| Female, No. (%) | 11 (29.7) | 11 (52.4) | .088 |
| Performance status, KPS ≥80, No. (%) | 35 (94.6) | 19 (90.5) | .615 |
| SOFA score at peak viral load (IQR) | 3 (2–4) | 4 (3–5) | .128 |
| Race, No. (%) | .776 | ||
| White | 26 (70.2) | 14 (66.7) | |
| Not White | 11 (29.8) | 7 (33.3) | |
| Diagnosis, No. (%) | .211 | ||
| AML | 18 (48.6) | 5 (23.8) | |
| ALL | 2 (5.4) | 4 (19) | |
| MDS | 8 (21.6) | 5 (23.8) | |
| Other | 9 (24.4)a | 7 (33.4)b | |
| Graft source, No. (%) | 1.000 | ||
| Peripheral blood | 32 (86.4) | 18 (85.7) | |
| Bone marrow | 5 (13.6) | 3 (14.3) | |
| Conditioning, No. (%) | .686 | ||
| Myeloablative | 13 (35.1) | 9 (42.8) | |
| Reduced intensity | 20 (54.0) | 11 (52.4) | |
| Nonmyeloablative | 4 (10.9) | 1 (4.8) | |
| ATG use, No. (%) | 5 (13.6) | 2 (9.5) | 1.000 |
| GVHD regimen, No. (%) | .776 | ||
| PTCy/tacrolimus/MMF | 11 (29.7) | 7 (33.3) | |
| PTCy/sirolimus/MMF | 26 (70.3) | 14 (66.7) | |
| CMV status, No. (%) | .775 | ||
| D+/R+ | 17 (45.9) | 11 (52.4) | |
| D+/R– | 3 (8.1) | 3 (14.3) | |
| D−/R+ | 10 (27.0) | 4 (19.0) | |
| D−/R− | 7 (19.0) | 3 (14.3) | |
| HHV-6 testing, No. (%) | .503 | ||
| Serial monitoring | 16 (43.2) | 11 (52.4) | |
| Symptomaticc | 21 (56.8) | 10 (47.6) |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; ATG, antithymocyte globulin; CML, chronic myeloid leukemia; CMV, cytomegalovirus; GVHD, graft-vs-host disease; KPS, Karnofsky Performance Score; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MPS, myeloproliferative syndrome; PLL, prolymphocytic leukemia; PTCy, post-transplant cyclophosphamide; SOFA, Sequential Organ Failure Assessment.
aCML (n = 1), MPS (n = 1), sickle cell anemia (n = 2), Hodgkin's lymphoma (n = 2), aplastic anemia (n = 2), PLL (n = 1).
bCML (n = 1), MPS (n = 3), adrenoleukodystrophy (n = 1), sickle cell (n = 2).
cNeurologic dysfunction, fever, cytopenias, rash.